Physician profile
Mark E Cormier
NPI 1922078401
$153,031.33
in general payments reported to CMS, 2019-2025
21 companies · $68K in 2025
The $68K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $253 · 2021: $307 · 2022: $375 · 2023: $23K · 2024: $61K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $151K · Education: $475 · Food and Beverage: $214 · Travel and Lodging: $55.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $151,033.17 |
| Education | $475.00 |
| Food and Beverage | $214.42 |
| Travel and Lodging | $55.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $151,563.19 | 2023-2025 | |
| Astellas Pharma US INC | $211.58 | 2019-2024 | Xtandi |
| Dendreon Pharmaceuticals LLC | $196.03 | 2019-2021 | |
| Myovant Sciences INC. | $153.43 | 2022 | |
| Verity Pharmaceuticals INC. | $148.16 | 2022-2024 | Trelstar |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2020 | |
| Coloplast Corp | $88.17 | 2019-2022 | |
| Abbvie INC. | $85.70 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $83.74 | 2023 | Orgovyx |
| Travere Therapeutics, INC. | $79.32 | 2019-2021 | |
| Janssen Biotech, INC. | $72.74 | 2021-2022 | |
| Rochester Medical Corporation | $61.22 | 2022 | |
| Angiodynamics, INC. | $32.37 | 2022 | |
| Bard Access Systems, INC. | $31.18 | 2019 | |
| Urogen Pharma, INC. | $17.99 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $16.59 | 2022 | |
| 180 Medical, INC. | $14.89 | 2020 | |
| Antares Pharma, INC. | $13.84 | 2021 | |
| Neotract INC. | $12.47 | 2020 | |
| Pfizer INC. | $12.29 | 2020 | |
| Convatec INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cormier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.